DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for long QT syndrome 9 — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleLong QT syndrome 9 maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for long qt syndrome 9 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
sodium voltage-gated channel alpha subunit 5 (SCN5A) — SCN5A is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet qdndrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6LQA · 3.3 Å · ligand Quinidine (QDN). Experimental structure, not a prediction.
What the evidence adds up to
The idiopathic long QT syndrome was described in 1983 as incompletely understood, and a prospective registry of patients was called for at that time. In a large French family with long QT1 syndrome followed over 25 years, adult male but not female gene carriers showed normalisation of the QTc interval after puberty. Dynamic analysis of the QT interval from Holter recordings permitted individual diagnosis in mutation carriers even when the QTc was normal, and the authors concluded this approach had diagnostic value for screening and management. The abstract does not report any drug or treatment.
In 2021, 24 clinicians with expertise in long-QT syndrome were presented with four challenging clinical scenarios. Of the 24, 23 voted and one abstained. There was consensus on the importance of diagnostic evaluation and of beta-blocker use. There was diversity of opinion about the appropriate use of other therapeutic measures in intermediate-risk individuals. The authors identified significant gaps in knowledge. No specific drug other than beta-blockers is mentioned, and no survival or response rates are given in any of the three abstracts.
No abstract provides data on any drug for long QT syndrome 9 specifically. The 1983 abstract calls for a registry but gives no results. The 2001 abstract concerns diagnostic methods, not treatment. The 2021 expert commentary reports consensus on beta-blockers but no trial outcomes. What is still missing are prospective trials that stratify patients by genotype, adequately powered to detect differences in cardiac events, and funded to follow patients long enough to measure hard endpoints such as sudden cardiac death.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
European Heart Journal · 1983 · 44 citations
The idiopathic long QT syndrome: the need for a prospective registry
AbstractThe pathogenetic mechanisms of idiopathic long QT syndrome have been largely, although not completely, understood; however, several critical issues highly relevant to the clinical management of patients affected by the syndrome need to be clarified. For this purpose, physicians are invited to a registry of such patients.
European Heart Journal · 2001 · 28 citations · open access
Dynamic analysis of the QT interval in long QT1 syndrome patients with a normal phenotype
AbstractAIMS: In families with the long QT syndrome penetrance may be low: up to 70% of gene carriers may have a normal QTc interval. These patients require therapy, similar to that in those with longer QTc intervals, but identifying them, using molecular analysis, is difficult to apply on a large scale. A large French family affected by the long QT1 syndrome was followed-up over a 25-year period. In adult males but not in females, the QTc interval normalized after puberty. We aimed to find clinical criteria, based on ambulatory ECG recordings so that we could improve diagnosis in affected members with a normal QTc. METHODS AND RESULTS: Linkage analysis and direct sequencing were an indicator of the long QT1 gene in our family. Reverse transcription-polymerase chain reaction analysis demonstrated abnormal transcripts in lymphocytes from silent gene carriers. The functional profile of mutated protein isoforms was investigated using the patch-clamp technique. Dynamic analysis of ventricular depolarization was conducted using Holter recordings in patients, and in sex- and age-matched controls. Circadian variations of the QTc interval and the QT/RR relationship were assessed. Sensitivity, specificity, and predictive values were evaluated for proposed clinical criteria. We found that dynamic analysis of the QT interval permitted individual diagnosis in mutation carriers even when the QTc interval was normal (adult males). CONCLUSION: Dynamic analysis of the QT interval is of diagnostic value in the long QT1 syndrome in patients with a normal phenotype. Clinical implications include improvement in screening and patient management.
Circulation Arrhythmia and Electrophysiology · 2021 · 19 citations · open access
Management of Congenital Long-QT Syndrome: Commentary From the Experts
AbstractWhile published guidelines are useful in the care of patients with long-QT syndrome, it can be difficult to decide how to apply the guidelines to individual patients, particularly those with intermediate risk. We explored the diversity of opinion among 24 clinicians with expertise in long-QT syndrome. Experts from various regions and institutions were presented with 4 challenging clinical scenarios and asked to provide commentary emphasizing why they would make their treatment recommendations. All 24 authors were asked to vote on case-specific questions so as to demonstrate the degree of consensus or divergence of opinion. Of 24 authors, 23 voted and 1 abstained. Details of voting results with commentary are presented. There was consensus on several key points, particularly on the importance of the diagnostic evaluation and of β-blocker use. There was diversity of opinion about the appropriate use of other therapeutic measures in intermediate-risk individuals. Significant gaps in knowledge were identified.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
